title: Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer.
abstract: Ptp4a3 (commonly known as PRL-3) is an enigmatic member of the Ptp4a family of prenylated protein tyrosine phosphatases that are highly expressed in many human cancers. Despite strong correlations with tumor metastasis and poor patient prognosis, there is very limited understanding of this gene family's role in malignancy. Therefore, we created a gene-targeted murine knockout model for Ptp4a3, the most widely studied Ptp4a family member. Mice deficient for Ptp4a3 were grossly normal. Fewer homozygous-null males were observed at weaning, however, and they maintained a decreased body mass. Although Ptp4a3 is normally associated with late-stage cancer and metastasis, we observed increased Ptp4a3 expression in the colon of wildtype mice immediately following treatment with the carcinogen azoxymethane. To investigate the role of Ptp4a3 in malignancy, we used the most commonly studied murine colitis-associated colon cancer model. Wildtype mice treated with azoxymethane and dextran sodium sulfate developed approximately 7-10 tumors per mouse in the distal colon. The resulting tumor tissue had 4-fold more Ptp4a3 mRNA relative to normal colon epithelium and increased PTP4A3 protein. Ptp4a3-null mice developed 50% fewer colon tumors than wildtype mice after exposure to azoxymethane and dextran sodium sulfate. Tumors from the Ptp4a3-null mice had elevated levels of both IGF1Rβ and c-MYC compared to tumors replete with Ptp4a3, suggesting an enhanced cell signaling pathway engagement in the absence of the phosphatase. These results provide the first definitive evidence implicating Ptp4a3 in colon tumorigenesis and highlight the potential value of the phosphatase as a therapeutic target for early stage malignant disease.
authors.affiliation: Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
authors.forename: Mark W
authors.initials: MW
authors.lastname: Zimmerman
authors.forename: Gregg E
authors.initials: GE
authors.lastname: Homanics
authors.forename: John S
authors.initials: JS
authors.lastname: Lazo
mesh_terms: D000818:Animals; D001397:Azoxymethane / Q000009:adverse effects / Q000494:pharmacology; D002273:Carcinogens / Q000633:toxicity; D003106:Colon / Q000201:enzymology* / Q000473:pathology; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000201:enzymology* / Q000235:genetics / Q000473:pathology / Q000628:therapy; D016264:Dextran Sulfate / Q000633:toxicity; D017353:Gene Deletion; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics / Q000378:metabolism*; D007413:Intestinal Mucosa / Q000201:enzymology* / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000151:congenital / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000628:therapy; D017027:Protein Tyrosine Phosphatases / Q000235:genetics / Q000378:metabolism*; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics / Q000378:metabolism
chemical_list: D002273:Carcinogens; D017874:Immediate-Early Proteins; C489428:Myc protein, mouse; D016271:Proto-Oncogene Proteins c-myc; C111534:Ptp4a3 protein, mouse; D016264:Dextran Sulfate; D017027:Protein Tyrosine Phosphatases; D001397:Azoxymethane
references.citation: Cancer Sci. 2005 Feb;96(2):69-76
references.pmid: 15723650
references.citation: Cancer Res. 2006 Oct 1;66(19):9625-35
references.pmid: 17018620
references.citation: Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8424-8
references.pmid: 8378314
references.citation: Science. 2001 Nov 9;294(5545):1343-6
references.pmid: 11598267
references.citation: Int J Mol Med. 2008 Aug;22(2):187-92
references.pmid: 18636172
references.citation: Int J Mol Sci. 2011 Feb 11;12(2):1133-45
references.pmid: 21541048
references.citation: Nat Protoc. 2007;2(8):1998-2004
references.pmid: 17703211
references.citation: Br J Cancer. 2006 Aug 7;95(3):347-54
references.pmid: 16832410
references.citation: Cancer Res. 2006 Mar 15;66(6):3153-61
references.pmid: 16540666
references.citation: J Biomed Biotechnol. 2011;2011:342637
references.pmid: 21274454
references.citation: Anticancer Agents Med Chem. 2011 Jan;11(1):99-108
references.pmid: 21291404
references.citation: Biochemistry. 2011 Sep 6;50(35):7579-90
references.pmid: 21806020
references.citation: J Carcinog. 2011 Mar 24;10:9
references.pmid: 21483655
references.citation: Cell. 1998 Sep 18;94(6):703-14
references.pmid: 9753318
references.citation: Cancer Res. 2007 Apr 1;67(7):2922-6
references.pmid: 17409395
references.citation: Cancer Res. 1993 Sep 1;53(17):3895-8
references.pmid: 8358714
references.citation: Cell. 1998 Mar 6;92(5):645-56
references.pmid: 9506519
references.citation: Cell. 2008 Jul 25;134(2):215-30
references.pmid: 18662538
references.citation: Genome Res. 2003 Mar;13(3):476-84
references.pmid: 12618378
references.citation: Mol Carcinog. 2003 May;37(1):51-9
references.pmid: 12720300
references.citation: Mol Cell. 2008 May 9;30(3):303-14
references.pmid: 18471976
references.citation: Lancet. 2002 Apr 13;359(9314):1301-7
references.pmid: 11965276
references.citation: BMC Cancer. 2011 Apr 06;11:122
references.pmid: 21466710
references.citation: J Biol Chem. 2007 Feb 23;282(8):5413-9
references.pmid: 17192274
references.citation: Mol Cell Biol. 1994 Jun;14(6):3752-62
references.pmid: 8196618
references.citation: Cancer Res. 2011 Jan 1;71(1):234-44
references.pmid: 21084277
references.citation: Biochem Biophys Res Commun. 2001 May 25;283(5):1061-8
references.pmid: 11355880
references.citation: Br J Cancer. 2008 Nov 18;99(10):1718-25
references.pmid: 19002188
references.citation: Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5860-5
references.pmid: 8650183
references.citation: J Biol Chem. 2012 Sep 14;287(38):32172-9
references.pmid: 22791713